Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,037,960
  • Shares Outstanding, K 2,624,593
  • Annual Sales, $ 24,384 M
  • Annual Income, $ 1,335 M
  • 60-Month Beta 0.52
  • Price/Sales 5.49
  • Price/Cash Flow 16.10
  • Price/Book 9.80
Trade AZN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.49
  • Number of Estimates 3
  • High Estimate 0.56
  • Low Estimate 0.41
  • Prior Year 0.50
  • Growth Rate Est. (year over year) -2.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.38 +0.32%
on 10/30/20
55.45 -8.85%
on 10/12/20
-4.26 (-7.77%)
since 09/30/20
3-Month
50.38 +0.32%
on 10/30/20
57.95 -12.79%
on 07/31/20
-7.35 (-12.70%)
since 07/30/20
52-Week
36.15 +39.81%
on 03/16/20
64.94 -22.17%
on 07/20/20
+1.52 (+3.10%)
since 10/30/19

Most Recent Stories

More News
Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

NVO : 64.23 (-3.17%)
SNY : 45.23 (-0.62%)
AZN : 50.43 (-1.25%)
LLY : 131.30 (-0.94%)
Smart Inhalers Market Worth USD 445.40 Million and Exhibit 41.1% CAGR till 2027; Increasing Prevalence of Asthma & COPD to Boost Growth: Fortune Business Insights(TM)

The global smart inhalers market size is set to gain impetus from the rising utilization of digital technology in the field of healthcare devices. It is aiding in increasing the efficiency of drug delivery...

MMM : 158.78 (+0.19%)
AZN : 50.43 (-1.25%)
GSK : 33.60 (-1.06%)
NVS : 77.95 (-0.15%)
VEGPF : 1.3156 (-3.97%)
Smart Inhalers Markets, 2025 - Inhibiting Factors and Impact of COVID-19 Shaping the Global Market

, /PRNewswire/ -- The report has been added to offering.

AZN : 50.43 (-1.25%)
GSK : 33.60 (-1.06%)
NVS : 77.95 (-0.15%)
OPK : 3.49 (-16.90%)
RMD : 191.88 (+6.89%)
TEVA : 8.59 (-1.72%)
VEGPF : 1.3156 (-3.97%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Innate Pharma SA (IPHA) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Innate Pharma SA ("Innate" or the "Company") (NASDAQ: IPHA) investors concerning the Company's possible violations of federal securities...

AZN : 50.43 (-1.25%)
IPHA : 4.04 (+1.13%)
FASENRA(R) eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial

High-level results from the PONENTE Phase IIIb open-label trial showed FASENRA(R) (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in OCS-dependent asthma patients with a broad...

AZN : 50.43 (-1.25%)
Point of Care Diagnostics Ease the Strain on Traditional Healthcare Systems

, /PRNewswire/ -- As cases of infection continue to rise nationwide, has become the latest addition to the quarantine list Tuesday, bringing the total number of affected U.S. states and territories...

AZN : 50.43 (-1.25%)
TOMDF : 0.0556 (-7.33%)
VIR : 31.31 (-7.45%)
CODX : 13.31 (-3.62%)
FLIR : 34.38 (-0.17%)
ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has received acceptance for its supplemental Biologics License Application (sBLA) and has...

AZN : 50.43 (-1.25%)
DSNKY : 26.2800 (+1.35%)
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know

Astrazeneca (AZN) closed at $52.48 in the latest trading session, marking a -1.11% move from the prior day.

AZN : 50.43 (-1.25%)
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.

AZN : 50.43 (-1.25%)
INCY : 85.42 (-1.84%)
MRNA : 68.20 (-4.32%)
VRTX : 209.34 (+1.13%)
Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance

Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.

JNJ : 136.42 (-0.56%)
AZN : 50.43 (-1.25%)
MRK : 74.79 (-1.45%)
HZNP : 75.11 (-3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 52.02
1st Resistance Point 51.54
Last Price 50.43
1st Support Level 50.50
2nd Support Level 49.94

See More

52-Week High 64.94
Fibonacci 61.8% 53.94
Fibonacci 50% 50.55
Last Price 50.43
Fibonacci 38.2% 47.15
52-Week Low 36.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar